Immunotherapy rechallenge after significant toxicity - can it be done successfully?

Area of Science:

• Oncology
• Immunology
• Clinical Medicine

Background:

• Cancer immunotherapy has revolutionized treatment but can cause immune-related adverse events (irAEs).
• Management of irAEs and the safety of reintroducing immunotherapy after irAEs are critical clinical questions.

Purpose of the Study:

• To determine the burden of hospital admissions for irAE management.
• To assess the feasibility and outcomes of immunotherapy rechallenge after prior irAEs.

Main Methods:

• Retrospective single-center study.
• Analysis of patients receiving immunotherapy between 2015-2018.
• Assessment of irAE occurrence, hospitalization rates, management strategies, and rechallenge outcomes.

Main Results:

• 22% of patients (69/307) were hospitalized for irAEs, with 2.6% requiring ICU admission and 1.9% mortality.
• Corticosteroids were used in 96% of hospitalizations; 21% required additional immunosuppression.
• 68% of patients (47/69) were rechallenged with immunotherapy; 40% of these experienced subsequent irAE hospitalizations.

Conclusions:

• Hospitalizations for irAE management represent a significant burden in patients receiving immunotherapy.
• Immunotherapy rechallenge after prior irAE hospitalization is feasible but associated with a substantial risk of recurrent toxicity.